IN THE CLAIMS

1. (Currently amended) A method of treating a host having hyperlipidemia comprising administering to the host an effective amount of a compound having the formula:



and pharmaceutically acceptable salts thereof, wherein R is selected from the group consisting of: H and acetyl.

~~a) H or acetyl,~~

~~b) $P(O)(OH)_2$,~~

~~c) P(O)(OH)(OM), wherein M is selected from the group consisting of an alkali metal salt and an alkaline earth metal salt,~~

~~d) $P(O)OM_2$ wherein M is each independently selected from the group consisting of alkali metal salts and alkaline earth metal salts,~~

~~e) Alkyl of 1 to 12 carbon atoms having 0 to 6 double bonds, said alkyl selected from the group consisting of substituted, unsubstituted, straight chain and branched alkyls,~~

~~f) (CH_2)n morpholine, wherein n=1-4,~~

~~g) morpholinomethylphenyl, ortho-aminophenyl or ortho-hydroxyphenyl,~~

~~h) (CH_2)n $COOR_2$ wherein n=1-4, R_2 is each selected from the group consisting of H, an alkali metal salt, an alkaline earth metal salt, NH_4+ and $N+(R_3)_4$ wherein R_3 is each independently selected from the group consisting of H and an alkyl of 1 to 4 carbon atoms, and~~

~~i) COR_1 wherein R_1 is selected from the group consisting of H, (CH_2)n CH_3 wherein n=0-6,~~

~~$(CH_2)n\ COOR_2$ wherein n=1-4 and R_2 is each selected from the group consisting of H, an alkali metal salt, an alkaline earth metal salt, NH_4^+ and $N^+(R_3)_4$, and $(CH_2)n\ N^+(R_3)_4$, wherein n=1-4 and R_3 is each independently selected from the group consisting of H and an alkyl of 1 to 4 carbon atoms.~~

2. (Original) The method of claim 1 wherein the compound is used in combination with other chemotherapeutic agents.

3. (Original) The method of claim 1 wherein R is selected from the group consisting of H and acetyl.

4. (Original) The method of claim 3 wherein the hyperlipidemia is selected from the group consisting of hypertriglyceridemia and hypercholesterolemia.

5. (Original) The method of claim 1 wherein the daily dose range of the compound is from about 0.5 mg to about 5000 mg.

6. (Original) The method of claim 1 further including incorporating the compound in a dosage form selected from the group consisting of a tablet, a troche, a dispersion, a suspension, a solution, a capsule, a patch, a syrup, an elixir and a wafer.

7. (Original) The method of claim 6 wherein the dosage form contains at least 0.1% by weight of the compound.

8. (Currently amended) A method for protecting a host from developing hyperlipidemia comprising administering to the host an effective amount of a compound having the formula:



and pharmaceutically acceptable salts thereof, wherein R is selected from the group consisting

of: H and acetyl.

~~a) H or acetyl,~~

~~b) $P(O)(OH)_2$,~~

~~c) P(O)(OH)(OM), wherein M is selected from the group consisting of an alkali metal salt and an alkaline earth metal salt,~~

~~d) $P(O)OM_2$ wherein M is each independently selected from the group consisting of alkali metal salts and alkaline earth metal salts,~~

~~e) Alkyl of 1 to 12 carbon atoms having 0 to 6 double bonds, said alkyl selected from the group consisting of substituted, unsubstituted, straight chain and branched alkyls,~~

~~f) (CH_2)n morpholine, wherein n=1-4,~~

~~g) morpholinomethylphenyl, ortho-aminophenyl or ortho-hydroxyphenyl,~~

~~h) (CH_2)n $COOR_2$ wherein n=1-4, R_2 is each selected from the group consisting of H, an alkali metal salt, an alkaline earth metal salt, NH_4+ and $N+(R_3)_4$ wherein R_3 is each independently selected from the group consisting of H and an alkyl of 1 to 4 carbon atoms, and~~

~~i) COR_1 wherein R_1 is selected from the group consisting of H, (CH_2)n CH_3 wherein n=0-6, (CH_2)n $COOR_2$ wherein n=1-4 and R_2 is each selected from the group consisting of H, an alkali metal salt, an alkaline earth metal salt, NH_4+ and $N+(R_3)_4$, and (CH_2)n $N+(R_3)_4$, wherein n=1-4 and R_3 is each independently selected from the group consisting of H and an alkyl of 1 to 4 carbon atoms.~~

9. (Original) The method of claim 8 wherein the compound is used in combination with other chemotherapeutic agents.

10. (Original) The method of claim 9 wherein the other chemotherapeutic agents are selected from the group consisting of Cyclosporin A and tacrolimus.

11. (Original) The method of claim 8 wherein R is selected from the group consisting of H and acetyl.

12. (Original) The method of claim 8 wherein said host is at risk for developing hyperlipidemia due to recent solid organ or bone marrow transplantation.

13. (Original) The method of claim 8 wherein the daily dose range of the compound is from about 0.5 mg to about 5000 mg.

14. (Original) The method of claim 8 further including incorporating the compound in a dosage form selected from the group consisting of a tablet, a troche, a dispersion, a suspension, a solution, a capsule, a patch, a syrup, an elixir and a wafer.

15. (Original) The method of claim 14 wherein the dosage form contains at least 0.1% by weight of the compound.